RecruitingPhase 4NCT04588077

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Sponsor

Mercy Medical Center

Enrollment

200 participants

Start Date

Sep 14, 2020

Study Type

INTERVENTIONAL

Conditions

Hepatitis B Cirrhosis, Liver Chronic Liver Disease

Summary

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Heplisav-B Injectable Product, 2-dose regimen and a biological treatment called Heplisav-B Injectable Product, 3-dose regimen for people with chronic liver disease, cirrhosis, liver, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.